DeepMed Research

NANG KUANG PHARMACEUTICAL CO., LTD.

🇹🇼Taiwan

Country: 🇹🇼Taiwan

Ownership: Public

Established: 1963-01-01

Employees: 501

Market Cap: -

Website: http://www.nangkuang.com.tw

Clinical Trials

A Phase I Study to Evaluate the Safety and PK of ND-340 in Healthy Volunteers

Phase 1

Completed

Conditions: Pain, Postoperative

Interventions: Drug: ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension
Drug: Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection

First Posted Date: 2022-10-20

Last Posted Date: 2024-11-27

Lead Sponsor: Nang Kuang Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT05588557

Locations: 🇨🇳
National Taiwan University Hospital, Taipei city, Taiwan

A Phase I Dose-escalation Study of a Single Administration of Extended-Release Injectable Suspension (ND-340)

Phase 1

Suspended

Conditions: Pain, Postoperative

Interventions: Drug: IV-PCA
Drug: ND-340

First Posted Date: 2020-08-17

Last Posted Date: 2023-11-09

Lead Sponsor: Nang Kuang Pharmaceutical Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT04515953

Locations: 🇨🇳
Nang Kuang Pharmaceutical Co., LTD, Tainan City, Taiwan (台灣), Taiwan

Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain

Phase 4

Completed

Conditions: Neuropathy
Pain

Interventions: Drug: Carbatin
Drug: Neurontin

First Posted Date: 2014-02-28

Last Posted Date: 2023-11-09

Lead Sponsor: Nang Kuang Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT02074267

Locations: 🇨🇳
Nang Kuang Pharmaceutical Co., LTD, Tainan, Taiwan

A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus

Phase 2

Terminated

Conditions: Localized Squamous Cell Carcinoma of the Esophagus

Interventions: Drug: ND-420
Procedure: Surgery
Drug: Cisplatin
Drug: fluorouracil

First Posted Date: 2013-12-23

Last Posted Date: 2020-05-20

Lead Sponsor: Nang Kuang Pharmaceutical Co., Ltd.

Target Recruit Count: 48

Registration Number: NCT02017600

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan

Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Terminated

Conditions: Neoplasms, Head and Neck
Cancer of the Head and Neck

Interventions: Drug: Oxaliplatin

First Posted Date: 2011-06-10

Last Posted Date: 2013-12-10

Lead Sponsor: Nang Kuang Pharmaceutical Co., Ltd.

Target Recruit Count: 46

Registration Number: NCT01370876

Locations: 🇨🇳
Taipei Mackay Memorial Hospital, Taipei, Taiwan

A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain

Phase 4

Completed

Conditions: Depression
Pain

Interventions: Drug: Smilon®
Drug: Placebo

First Posted Date: 2010-05-10

Last Posted Date: 2011-06-09

Lead Sponsor: Nang Kuang Pharmaceutical Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT01119924

Locations: 🇨🇳
Nang Kuang Pharmaceutical Co., LTD, Tainan, Xinhua Township, Taiwan

Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease

Phase 4

Terminated

Conditions: Cardiovascular Disease
Hypercholesterolemia
Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Dehypotin

First Posted Date: 2010-04-22

Last Posted Date: 2011-06-09

Lead Sponsor: Nang Kuang Pharmaceutical Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT01108978

Locations: 🇨🇳
Nang Kuang Pharmaceutical Co., LTD, Tainan, Xinhua Township, Taiwan

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy